Proposed treatment targets for the management of inflammatory bowel disease (IBD) have
moved beyond symptomatic improvement towards more objective end points, such as …

For all biologics in IBD, there is a positive correlation between drug concentrations and
favorable therapeutic outcomes. Reactive TDM is the new standard of care for optimizing …

Abstract Background and Aims Therapeutic drug monitoring [TDM] has proven to be
effective for optimising anti-tumour necrosis factor [TNF] therapy in inflammatory bowel …

Anti-tumor necrosis factor (anti-TNF) therapy has been successfully used as first-line
biologic treatment for moderate-to-severe inflammatory bowel disease (IBD), in both “step …

Background & Aims Therapeutic drug monitoring (TDM) is widely available for biologic
therapies in patients with inflammatory bowel disease (IBD). We reviewed current data and …

Background Therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD)
patients receiving anti‐tumour necrosis factor (TNF) agents can help optimise outcomes …

Abstract Background and Aims We undertook a systematic review and meta-analysis
examining the effectiveness of therapeutic drug monitoring [TDM] to improve clinical …

Background & Aims Proactive therapeutic drug monitoring (TDM) has been proposed to
improve outcomes in patients with inflammatory bowel disease (IBD) treated with tumor …

Background Tumour necrosis factor (TNF)‐antagonists have an established role in the
treatment of inflammatory bowel diseases (IBDs), however, subtherapeutic drug levels and …

Current available anti-inflammatory drugs, in particular monoclonal antibodies directed
against the cytokine tumor necrosis factor α (TNF), have greatly enhanced the treatment of …